Personal information

Activities

Collapse all

Employment (4)

Tongji University the Tenth hospital/Medical School Tongji University: Shanghai, CN

2019-09-01 to present | Professor (Medical School )
Employment
Source: Self-asserted source
Yufeng Shi

Memorial Sloan Kettering Cancer Center: New York, New York, US

2015-07-01 to 2019-08-30 | Research Associate
Employment
Source: Self-asserted source
Yufeng Shi

The University of Texas Southwestern Medical Center Medical School: Dallas, TX, US

2011-09-01 to 2015-06-30 | Assistant Instructor
Employment
Source: Self-asserted source
Yufeng Shi

Weill Cornell Medicine: New York, NY, US

2007-09-01 to 2011-08-30 | Postdoctor (Weill Institute for Molecular and Cellular Biology)
Employment
Source: Self-asserted source
Yufeng Shi

Education and qualifications (2)

Chinese Academy of Sciences Shanghai Branch: Xuhui District, Shanghai, CN

2002-09-01 to 2007-07-01 | Doctor of Philosophy (Institute of Biochemistry and Cell Biology)
Education
Source: Self-asserted source
Yufeng Shi

Nankai University College of Life Sciences: Tianjin, Tianjin, CN

1998-09-01 to 2002-06-30 | Master (Department of Biology)
Education
Source: Self-asserted source
Yufeng Shi

Funding (3)

Research on the mechanism and function of cytochrome oxidase assembly factor COA3 regulating mitochondrial re-programming affecting the activity of glioblastoma stem cells

2021-01 to 2024-12 | Grant
National Natural Science Foundation of China (Beijing, CN)
Source: Self-asserted source
Yufeng Shi

Study on the effect and mechanism of OXPHOS inhibitor Morin targeting SWI/SNF mutant lung cancer

2020-10 to 2023-09 | Grant
Science and Technology Commission of Shanghai Municipality (shanghai, CN)
Source: Self-asserted source
Yufeng Shi

Preclinical development of targeting mitochondria anticancer small molecules

2020-05 to 2023-05 | Contract
Nanjing Shijiang Pharmaceutical Technology Co., Ltd. (Nanjing, CN)
Source: Self-asserted source
Yufeng Shi

Works (5)

Upregulated YB-1 protein promotes glioblastoma growth through a YB-1/CCT4/mLST8/mTOR pathway

Journal of Clinical Investigation
2022-04-15 | Journal article
DOI: 10.1172/jci146536
Part of ISSN: 1558-8238
Contributors: Yufeng Shi
Source: Self-asserted source
Yufeng Shi

Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development

Signal Transduction and Targeted Therapy
2021-12 | Journal article
DOI: 10.1038/s41392-021-00745-7
Part of ISSN: 2059-3635
Contributors: Yufeng Shi
Source: Self-asserted source
Yufeng Shi

Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner

Signal Transduction and Targeted Therapy
2020-12 | Journal article
DOI: 10.1038/s41392-020-00353-x
Part of ISSN: 2059-3635
Contributors: Yufeng Shi
Source: Self-asserted source
Yufeng Shi

Cell Lineage-Based Stratification for Glioblastoma

Cancer Cell
2020-09 | Journal article
DOI: 10.1016/j.ccell.2020.06.003
Part of ISSN: 1535-6108
Contributors: Yufeng Shi
Source: Self-asserted source
Yufeng Shi

Mitochondria as a target in cancer treatment

MedComm
2020-09 | Journal article
DOI: 10.1002/mco2.16
Part of ISSN: 2688-2663
Part of ISSN: 2688-2663
Contributors: Yufeng Shi
Source: Self-asserted source
Yufeng Shi

Peer review (1 review for 1 publication/grant)

Review activity for Nature communications (1)
How many people are using ORCID?